Ionis CEO exercises options and sells shares
Ionis Pharmaceuticals Chief Executive Officer Brett P. Monia reported an exercise-and-sell transaction in company stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Ionis Pharmaceuticals Chief Executive Officer Brett P. Monia reported an exercise-and-sell transaction in company stock. On May 13–14, Monia exercised options to acquire a total of 4,536 shares of common stock at an exercise price of $32.60 per share, then sold the same number of shares in open-market trades at weighted average prices of about $78.01 and $78.68. The sales were carried out under a pre-arranged Rule 10b5-1 Trading Plan adopted on December 8, 2025. Following these transactions, Monia directly holds 242,662 shares of Ionis common stock, indicating that only a small portion of the position was sold.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 3,220 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,220 | $32.60 | $105K |
| Sale | Common Stock | 3,220 | $78.6793 | $253K |
| Exercise | Non-Qualified Stock Option (right to buy) | 1,316 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,316 | $32.60 | $43K |
| Sale | Common Stock | 1,316 | $78.013 | $103K |
Footnotes (3)
- F1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.025 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.075 to $79.01 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
Key Figures
Key Terms
Rule 10b5-1 Trading Plan regulatory
Non-Qualified Stock Option financial
weighted average price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Ionis (IONS) CEO Brett Monia report?
Were the recent Ionis (IONS) CEO stock sales pre-planned?
What stock options did the Ionis (IONS) CEO exercise in this Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.